Bellevue Group AG Sells 26,430 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Bellevue Group AG lowered its position in 10x Genomics, Inc. (NASDAQ:TXG) by 8.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 281,881 shares of the company’s stock after selling 26,430 shares during the period. Bellevue Group AG owned approximately 0.23% of 10x Genomics worth $6,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Swedbank AB purchased a new stake in shares of 10x Genomics in the first quarter worth approximately $675,000. Quent Capital LLC increased its stake in 10x Genomics by 83.9% in the second quarter. Quent Capital LLC now owns 8,916 shares of the company’s stock worth $173,000 after purchasing an additional 4,068 shares during the period. SG Americas Securities LLC lifted its position in shares of 10x Genomics by 604.9% during the second quarter. SG Americas Securities LLC now owns 101,344 shares of the company’s stock worth $1,971,000 after purchasing an additional 86,967 shares during the last quarter. Mirador Capital Partners LP boosted its stake in shares of 10x Genomics by 115.0% during the second quarter. Mirador Capital Partners LP now owns 61,967 shares of the company’s stock valued at $1,205,000 after purchasing an additional 33,142 shares during the period. Finally, SteelPeak Wealth LLC bought a new position in shares of 10x Genomics in the second quarter worth about $413,000. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, October 10th. Leerink Partners assumed coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 price target for the company. Citigroup dropped their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. Barclays decreased their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, The Goldman Sachs Group dropped their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.19.

10x Genomics Stock Performance

NASDAQ:TXG opened at $15.90 on Friday. The company’s 50-day simple moving average is $16.89 and its 200-day simple moving average is $19.55. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $57.90.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The company had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. 10x Genomics’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.51) earnings per share. On average, sell-side analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.